Literature DB >> 24509465

Restaging of locally advanced rectal cancer with magnetic resonance imaging and endoluminal ultrasound after preoperative chemoradiotherapy: a systemic review and meta-analysis.

Ri-Sheng Zhao1, Hui Wang, Zhi-Yang Zhou, Qian Zhou, Michael W Mulholland.   

Abstract

BACKGROUND: Magnetic resonance imaging and endoluminal ultrasound play an important role in the restaging of locally advanced rectal cancer after preoperative chemoradiotherapy, yet their diagnostic accuracy is still controversial.
OBJECTIVE: Meta-analysis was performed to estimate the diagnostic performance of MRI and endoluminal ultrasound. DATA SOURCES: Electronic databases from 1996 to March 2012 were searched. STUDY SELECTION AND
INTERVENTIONS: Either MRI or endoluminal ultrasound was used to restage rectal cancer after chemoradiotherapy or radiation. MAIN OUTCOME MEASURES: T category, lymph node, and circumferential resection involvement were measured.
RESULTS: The sensitivity estimate for rectal cancer diagnosis (T0) by endoluminal ultrasound (37.0%; 95% CI, 24.0%-52.1%) was higher (p = 0.04) than the sensitivity estimate for MRI (15.3%; 95% CI, 6.5%-32.0%). For T3-4 category, sensitivity estimates of MRI and endoluminal ultrasound were comparable, 82.1% and 87.6%, whereas specificity estimates were poor (53.5% and 66.4%). For lymph node involvement, there was no significant difference between the sensitivity estimates for MRI (61.8%) and endoluminal ultrasound (49.8%). Specificity estimates for MRI and endoluminal ultrasound were 72.0% and 78.7%. For circumferential resection margin involvement, MRI sensitivity and specificity were 85.4% and 80.0%. LIMITATIONS: To identify the heterogeneity, metaregression was performed on covariates. However, few of the covariates were identified to be statistically significant because of the lack of adequate original data.
CONCLUSION: Accurate restaging of locally advanced rectal cancer by MRI and endoluminal ultrasound is still a challenge. Identifying T0 rectal cancer by imaging is not reliable. Before performing surgery, restaging is important, but some of the T0-2 patients are likely overestimated as T3-4. Both modalities for lymph node involvement are not very good. Magnetic resonance imaging may be a good method to reassess circumferential resection margin.

Entities:  

Mesh:

Year:  2014        PMID: 24509465     DOI: 10.1097/DCR.0000000000000022

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  23 in total

1.  [Lymph node metastases in ypT1/2 rectal cancer after neoadjuvant chemoradiotherapy : The Achilles heel of organ-preserving operative procedures?].

Authors:  T Sprenger; H Rothe; T Beissbarth; L-C Conradi; A Kauffels; K Homayounfar; C L Behnes; C Rödel; T Liersch; M Ghadimi
Journal:  Chirurg       Date:  2016-07       Impact factor: 0.955

2.  Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017.

Authors:  C A Kim; S Ahmed; S Ahmed; B Brunet; H Chalchal; R Deobald; C Doll; M P Dupre; V Gordon; R M Lee-Ying; H Lim; D Liu; J M Loree; J P McGhie; K Mulder; J Park; B Yip; R P Wong; A Zaidi
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

3.  Can CRM Status on MRI Predict Survival in Rectal Cancers: Experience from the Indian Subcontinent.

Authors:  Mihir Chandarana; Supreeta Arya; Jean-Louis de Menezes; Reena Engineer; Vikas Ostwal; Prachi Patil; Suman Kumar; Rohit Dusane; Ashwin D'souza; Avanish Saklani
Journal:  Indian J Surg Oncol       Date:  2019-02-21

4.  Assessment of remaining tumour involved lymph nodes with MRI in patients with complete luminal response after neoadjuvant treatment of rectal cancer.

Authors:  Per Loftås; Margrét Sturludóttir; Olof Hallböök; Karin Almlöv; Gunnar Arbman; Lennart Blomqvist
Journal:  Br J Radiol       Date:  2018-05-10       Impact factor: 3.039

5.  Risk factors for circumferential R1 resection after neoadjuvant radiochemotherapy and laparoscopic total mesorectal excision: a study in 233 consecutive patients with mid or low rectal cancer.

Authors:  Clotilde Debove; Léon Maggiori; Amélie Chau; Frédéric Kanso; Marianne Ferron; Yves Panis
Journal:  Int J Colorectal Dis       Date:  2014-12-04       Impact factor: 2.571

6.  Development and validation of an MRI-based model to predict response to chemoradiotherapy for rectal cancer.

Authors:  Philippe Bulens; Alice Couwenberg; Karin Haustermans; Annelies Debucquoy; Vincent Vandecaveye; Marielle Philippens; Mu Zhou; Olivier Gevaert; Martijn Intven
Journal:  Radiother Oncol       Date:  2018-01-31       Impact factor: 6.280

Review 7.  Locally Advanced Rectal Cancer Evaluation by Magnetic Resonance Imaging after Neoadjuvant Therapy on Decision Making: Cancer Center Experience and Literature Review.

Authors:  Alejandro Recio-Boiles; Hytham Hammad; Krisha Howell; Bobby T Kalb; Valentine N Nfonsam; Aaron J Scott; Hani M Babiker; Emad Elquza
Journal:  J Gastrointest Cancer       Date:  2020-03

8.  MRI can be used to assess advanced T-stage colon carcinoma as well as rectal carcinoma.

Authors:  Akitoshi Inoue; Shinichi Ohta; Norihisa Nitta; Masahiro Yoshimura; Tomoharu Shimizu; Masaji Tani; Ryoji Kushima; Kiyoshi Murata
Journal:  Jpn J Radiol       Date:  2016-10-18       Impact factor: 2.374

Review 9.  Surgeon perspectives on the use and effects of neoadjuvant chemoradiation in the treatment of rectal cancer: a comprehensive review of the literature.

Authors:  Sami A Chadi; Marianna Berho; Steven D Wexner
Journal:  Langenbecks Arch Surg       Date:  2015-08-07       Impact factor: 3.445

10.  Pretreatment identification of patients likely to have pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  Frederik J van der Sluis; Henderik L van Westreenen; Boudewijn van Etten; Barbara L van Leeuwen; Geertruida H de Bock
Journal:  Int J Colorectal Dis       Date:  2017-12-15       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.